By Associate Professor Megan Amanda Crumbaker

Journal articles

Talmor B; Baranseh J; Charas T; Shirron N; Goshenlago T; Crumbaker M; Joshua A; Peer A, 2026, 'De-Escalation Therapy in Metastatic Prostate Cancer: A Retrospective Study on Intermittent ADT and ARPI Combination Treatment', Clinical Genitourinary Cancer, 24, http://dx.doi.org/10.1016/j.clgc.2026.102639

Khan S; Papa N; Hioki T; Crumbaker M; Lee S-T; Weickhardt A; Sharma S; Weir S; Luckerath K; Kwan E; Emmett L, 2026, 'A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).', Journal of Nuclear Medicine, pp. jnumed.126.272714, http://dx.doi.org/10.2967/jnumed.126.272714

Urban RQ; Keerthikumar S; Lau P; Cuffe G; Teng L; Clark AK; Risbridger GP; Taylor RA; Crumbaker M; JOSHUA A; Lawrence MG, 2026, 'Abstract 2697: Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy response in prostate cancer.', Cancer Research, 86, pp. 2697 - 2697, http://dx.doi.org/10.1158/1538-7445.am2026-2697

Sandhu S; Joshua AM; Emmett L; Bressel M; Anton A; Spain L; Horvath LG; Pasam A; Tolmeijer SH; Akhurst TJ; Alipour R; Banks P; Buteau JP; Cassidy E; Crumbaker M; Dhiantravan N; Xu W; Chan J; Hitchen N; Scalzo M; Ravi Kumar AS; Kong G; Wallace R; Williams N; Williams S; Haynes NM; Neeson P; Wyatt AW; Hicks RJ; Hofman MS, 2026, '[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study', Lancet Oncology, 27, pp. 470 - 479, http://dx.doi.org/10.1016/S1470-2045(26)00017-3

Ayati N; Papa N; Crumbaker M; Subramaniam S; Joshua AM; Alipour R; Iravani A; Askari E; Khan S; Yadav S; Eiber M; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Nguyen A; Hofman MS; Sandhu S; Hioki T; van Oorschodt JCJ; Devitt K; Willowson K; Sharma S; Stancu A; Chauvie S; Wilson P; Martin AJ; Thomas H; Stockler MR; Davis ID; Emmett L, 2026, '177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer', Radiology, 319, http://dx.doi.org/10.1148/radiol.252672

Emmett L; Swiha M; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Pathmanandavel S; Hope T; Ayati N; Hofman MS; Sandhu S; Niu C; Martin AJ; Thomas H; Stockler MR; Davis ID, 2026, 'Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial', Nature Cancer, 7, pp. 622 - 630, http://dx.doi.org/10.1038/s43018-026-01140-3

Talmor B; Harris CA; Gianacas C; Pook D; Tan TH; Davis ID; Krieger L; Marx G; Anton A; Sharma S; Goh JC; Xu K; Pranavan G; Dhillon HM; Antonarakis ES; Denmeade SR; Horvath L; Oakes SR; Allen R; Fontela A; Reich E; Crumbaker M; Hurwitz J; Joshua AM, 2026, 'WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide', European Urology Oncology, 9, pp. 472 - 478, http://dx.doi.org/10.1016/j.euo.2026.02.004

Zarba M; O’Sullivan DE; Hajj Chehade RE; McKay RR; Pal SK; Beuselinck B; Donskov F; Lalani A-K; Crumbaker M; Li H; Alva AS; Powles T; Takemura K; Kollmansberger C; Wong SS; Wood LA; Ludwig L; Velasco GD; Cheung W; Choueiri TK; Heng DYC, 2026, 'Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)', Kidney Cancer, http://dx.doi.org/10.1177/24684562251411428

Talmor B; Marastoni S; Lau B; Yam A; Yeung N; Lin HM; Li ZJ; Woo H; Pranavan G; Stricker P; Horvath L; Koritzinsky M; Wouters B; Crumbaker M; Joshua A, 2026, 'A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results', Cancer Research Communications, 6, pp. 687 - 697, http://dx.doi.org/10.1158/2767-9764.CRC-26-0010

Jude E; Liow E; Shapiro J; Azad AA; Crumbaker M; Pranavan G; Hocking C; Roncolato F; Smith A; Wong S; Anton A; Johns J; Gibbs P; Tran B; Weickhardt A, 2026, 'Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia', Asia Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.70164

Emmett L; Papa N; Sartor O; Morris MJ; Subramaniam S; Crumbaker M; Ayati N; Chen J; Herrmann K; Gafita A; Swiha M; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Ho B; Khan S; Tan TH; Bills M; Nguyen A; Thein T; Sidhom G; Wong K; Martin AJ; Hofman MS; Sandhu S; Thomas H; Stockler MR; Davis ID, 2026, 'Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)', European Urology, http://dx.doi.org/10.1016/j.eururo.2026.03.026

Hansen AR; Ngai S; Goh JC; Wyld D; Gan CL; Katchel L; O'Mahoney E; Griffiths MR; Brady J; Kuchel A; Latter M; Mason R; Santoro P; Crumbaker M; Baronet MC; Grace R; Brilhante J; Rose S; Kryza T; Kuan K; Wiegert E; Karmann A; Pattison DA, 2026, 'Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical Imaging', Journal of Medical Imaging and Radiation Sciences, 57, pp. 102292, http://dx.doi.org/10.1016/j.jmir.2026.102292

Shekar S; Crumbaker M; Joshua A; Yam A; Stricker P; Yuen C; Ende D; Namdarian B; Thompson J; Kooner R; O'Neill G; Mo J; Sim HW; Hruby G; Kasraei F; Ho A; De Leon J, 2025, 'Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience', Bjui Compass, 6, http://dx.doi.org/10.1002/bco2.70055

Lin KL; Talmor B; Crumbaker M; Joshua AM, 2025, 'A Review of Hot Flash Management in Patients with Prostate Cancer', Journal of Clinical Endocrinology and Metabolism, 110, pp. 2509 - 2519, http://dx.doi.org/10.1210/clinem/dgaf302

Emmett L; Papa N; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Sandhu S; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ayati N; Niu C; Hofman MS; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 1168 - 1177, http://dx.doi.org/10.1016/S1470-2045(25)00339-0

Lawrence MG; Keerthikumar S; Townley SL; Clark AK; Cuffe GB; Laven-Law G; Hanson AR; Shrestha RK; Knutson TP; Richards MG; Teng L; Choo N; Crumbaker M; Joshua AM; Corey E; Nelson PS; Dehm SM; Risbridger GP; Tilley WD; Hickey TE; Taylor RA; Selth LA, 2025, 'Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants', European Urology Focus, 11, pp. 790 - 800, http://dx.doi.org/10.1016/j.euf.2025.03.017

Pathmanandavel S; Crumbaker M; Nguyen A; O. Yam A; Wilson P; Niman R; Ayers M; Sharma S; Eu P; J. Martin A; R. Stockler M; M. Joshua A; Emmett L, 2025, 'Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial', Advances in Radiotherapy & Nuclear Medicine, 3, pp. 43 - 43, http://dx.doi.org/10.36922/arnm025110011

Kwan EM; Ng SWS; Tolmeijer SH; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Herberts C; Davis ID; Hofman MS; Azad AA; Wyatt AW; Zhang AY; Yip S; Williams SG; Weickhardt A; Wallace R; Violet JA; Tran B; Thomas P; Thang SP; Tan TH; Subramaniam S; Spain L; Schembri G; Saghebi J; Rutherford NK; Roselt P; Roach P; Redfern AD; Ravi Kumar AS; Rana N; Ramdave S; Pokorski I; Pook D; Pattison DA; Nguyen A; Ng S; Murphy DG; Moodie K; McDonald W; McJannett MM; McCarthy M; Lin P; Lewin J; Lawrence N; Langford A; Kong G; Kirkwood ID; Hung T; Hsiao E; Hicks RJ; Haskali MB; Hamid A; Guminski AD; Goh JC; Gedye C; Ford K; Dhiantravan N; Crumbaker M; Chua W; Campbell L; Beaulieu A; Banks P; Bailey DL; Alipour R; Akhurst T, 2025, 'Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial', Nature Medicine, 31, pp. 2722 - 2736, http://dx.doi.org/10.1038/s41591-025-03704-9

Kostos L; Buteau JP; Kong G; Tran B; Haskali MB; Fahey M; Crumbaker M; Emmett L; Hofman MS; Azad AA, 2025, 'Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 66, pp. 572 - 578, http://dx.doi.org/10.2967/jnumed.124.269252

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Nguyen A; Ravi Kumar AS; Lin P; Butler P; Thomas H; Martin AJ; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, pp. tps298 - tps298, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Zarba M; O'Sullivan D; El Hajj Chehade R; McKay RR; Pal SK; Beuselinck B; Donskov F; Lalani A-KA; Crumbaker M; Li H; Alva AS; Powles T; Takemura K; Kollmannsberger CK; Wong SS; Wood LA; de Velasco G; Cheung WY; Choueiri TK; Heng DYC, 2025, 'Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, 43, pp. 479 - 479, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.479

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura K; Kollmannsberger CK; Crumbaker M; Lalani AKA; Powles T; Ebrahimi H; McKay RR; Lee JL; Kanesvaran R; Choueiri TK; Heng DYC, 2025, 'Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis', European Urology Oncology, 8, pp. 171 - 178, http://dx.doi.org/10.1016/j.euo.2024.12.011

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Shekar S; Hall A; Pham J; Crumbaker M; Liu J; Talmor B; Sim HW; Joshua AM, 2025, 'Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials', Endocrine Oncology, 5, http://dx.doi.org/10.1530/EO-25-0027

Emmett L; Zheng A; Jin C; Papa N; Khan S; Ayati N; Susman T; Ngai K; Nelson A; Sharma S; Anand R; John N; Crumbaker M; Nguyen A; Herrmann K, 2025, '‘One button push’ fully automated PSMA PET quantification: Correlation with progression free and overall survival in patients undergoing [177Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer.', Journal of Clinical Oncology, 43, pp. 5054 - 5054, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5054

Hansen AR; Pattison DA; Gan CL; Goh JCH; Ngai S; Katchel L; Holmes I; Baker S; Campbell L; Brady J; Santoro P; Crumbaker M; Baronet M; Rose S; Adamovich AA; Puttick S; Kryza T; Kuan K; Karmann A; Wyld DK, 2025, '2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial', Annals of Oncology, 36, pp. s1298 - s1299, http://dx.doi.org/10.1016/j.annonc.2025.08.3004

Sandhu SK; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Chan J; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Alipour R; Kong G; Kumar ASR; Tran B; Tolmeijer SH; Buteau JP; Williams S; Hicks RJ; Hofman MS, 2025, '2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 36, pp. s1300 - s1301, http://dx.doi.org/10.1016/j.annonc.2025.08.3007

Crumbaker M; Gupta S; Papa N; Hartmann N; Wenstrup RJ; Sandhu SK; Joshua AM; Subramaniam S; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Yip S; Subhash V; Thomas H; Hofman MS; Stockler MR; Davis ID; Emmett L, 2025, '2394P Circulating tumour cell (CTC) characteristics associated with survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) in a randomised trial of enzalutamide with or without [177Lu]Lu-PSMA-617 (ENZA-p; ANZUP 1901)', Annals of Oncology, 36, pp. s1303 - s1304, http://dx.doi.org/10.1016/j.annonc.2025.08.3010

Emmett L; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Hofman MS; Sandhu S; Martin AJ; Thomas H; Davis ID; Stockler MR; Group TAANZUAPCT, 2025, 'Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901).', Journal of Clinical Oncology, 43, pp. 5011 - 5011, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5011

Sabahi Z; Papa N; Fendler WP; Nguyen A; Wong K; Ayati N; Ho B; Chen J; Cusick T; Burger I; Crumbaker M; Marx GM; Sharma S; Frydenberg M; Sandhu S; Davis ID; Stockler MR; Sweeney C; Joshua AM; Emmett L; Group TAANZUAPCT, 2025, 'Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.', Journal of Clinical Oncology, 43, pp. 5091 - 5091, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5091

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 65, pp. 1939 - 1944, http://dx.doi.org/10.2967/jnumed.124.267606

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura KN; Kollmannsberger CK; Crumbaker M; Lalani AKA; Powles T; Pal SK; McKay RR; Lee JL; Kanesvaran R; Choueiri TK; Heng DYC, 2024, 'Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.', Journal of Clinical Oncology, 42, pp. 390 - 390, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.390

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. s975 - s976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; De Abreu Lourenço R; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', Journal of Clinical Oncology, 41, pp. tps5099 - tps5099, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5099

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Pemberton L; Allen C; Handel E; Weickhardt AJ; Tran B; Crumbaker M; Shapiro JD; Risbridger GP; Pook DW, 2023, 'Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).', Journal of Clinical Oncology, 41, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.158

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Back to profile page